Calidi Biotherapeutics CLDI Cash Flow Statement (2021-2026)

NYSE CLDI
$0.76 -0.01 (-1.31%)
As of: Oct 21, 2026 · 3:46 PM EDT
Reported Financials

Calidi Biotherapeutics Quarterly Cash Flow Statement

Periods 18 quarters
Latest Jun 2026

Calidi Biotherapeutics cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 18 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Operating Activities
Net Income -7.74M-4.58M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.23M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M-4.06M-4.16M
Depreciation and DepletionDep. & Depletion 0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges 0.12M0.20M0.02M0.20M-0.28M0.02M0.02M0.01M0.00M
Depreciation & Amortization (CF)Dep. & Amort. 0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.39M0.10M0.10M0.10M0.42M0.10M
Share-based CompensationStock Comp. 1.06M1.06M1.43M1.08M1.11M1.19M0.89M0.75M0.69M0.63M0.61M0.52M0.53M0.45M
Gains from Investment SecuritiesGains Investment 0.00M0.00M0.13M0.03M0.01M
Other non-cash itemsOther Non-Cash -2.09M-4.03M-0.46M-6.76M0.10M1.28M0.26M0.27M0.27M0.28M0.29M0.30M0.30M
Change in Working Capital
Change in Account PayablesChange Payables 0.00M536.001.56M0.06M0.02M-1.69M-5.98M1.49M0.97M0.17M-0.61M-1.17M-0.75M0.02M-0.19M-0.40M
Change in Accured ExpensesChange Accured Exp. -0.02M-0.01M2.03M-0.22M0.24M1.25M-0.79M0.58M-0.39M-0.71M-0.19M-0.57M-1.69M0.24M0.26M-0.81M
Change in Other Operating AssetsOther Assets Change -0.09M-0.11M-0.12M0.15M0.28M0.28M1.30M0.35M-1.58M-0.01M-0.47M0.25M0.32M-0.16M-0.12M0.00M
Change in Other Operating LiabilitiesOther Liabilities Change 0.04M-0.22M-0.23M1.28M-0.24M-0.25M-0.26M-0.27M-0.28M-0.49M-0.30M-0.31M
Other Working Capital ChangesOther WC Changes 0.09M0.11M0.12M-0.15M-0.25M-0.50M-1.53M0.93M1.34M-0.24M0.21M-0.52M-0.60M-0.32M-0.19M-0.32M
Cash from OperationsCash from Ops. -0.47M-0.27M-8.60M-3.88M-3.11M-5.17M-13.52M-5.19M-3.83M-5.49M-4.95M-5.42M-7.13M-4.88M-4.24M-5.05M
Investing Activities
Capital ExpendituresCapex 0.16M0.14M0.31M0.07M0.07M0.01M0.01M0.01M0.01M0.06M0.03M0.03M
Change in Property, Plant and EquipmentChange in PP&E -0.16M-0.14M-0.31M-0.07M-0.07M-0.01M-0.01M-0.01M-0.01M-0.06M-0.03M-0.03M
Purchase of InvestmentsInvestments Purchased 0.43M0.93M
Sale and Maturity of InvestmentsInvestments Sold 190.01M
Other Investing ActivitiesOther investing 0.04M
Cash from Investing ActivitiesCash from Investing -0.33M-0.16M-0.14M-0.24M-0.06M-0.04M-0.01M-0.01M-0.01M-0.01M-0.06M-0.03M-0.08M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance 2.40M0.65M0.75M0.50M3.20M0.60M
Long-Term Debt RepaymentsLT Debt Repayment 0.02M0.02M0.02M0.02M1.35M0.02M-1.18M0.02M0.02M1.47M0.39M0.40M0.03M
Non-Current Debt 2.40M0.63M1.60M0.40M3.18M1.18M0.58M-0.02M-1.47M-0.39M-0.40M-0.03M
Net Debt Issuances and RepaymentsNet Debt Issuance 2.40M0.63M1.60M0.40M3.18M1.18M0.58M-0.02M-1.47M-0.39M-0.40M-0.03M
Change in Capital Stock
Common Stock IssuedStock Issued 0.11M0.18M0.05M2.81M2.74M5.09M3.50M2.78M-2.78M3.27M
Net Shares Issued and RepurchasedNet Shares Issued 0.11M0.18M0.05M2.81M2.74M5.09M3.50M2.78M-2.78M3.27M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued 0.17M9.76M
Net Equity Issued and RepurchasedNet Equity Issued 0.11M0.18M0.22M12.57M2.74M5.09M3.50M2.78M-2.78M3.27M
Other financing activitiesOther financing 2.69M1.28M0.49M-3.27M-3.26M0.09M-0.88M1.73M-0.50M-0.22M-0.16M-0.34M-0.12M
Cash from Financing ActivitiesCash from Financing 7.77M4.32M3.79M6.58M21.64M-2.96M3.01M5.20M6.05M13.11M8.11M-0.47M9.48M0.34M
Additional items
Exchange Rate EffectFX Effect 0.01M0.02M-0.02M0.02M-0.01M-0.03M0.02M0.01M
Change in Cash -0.47M-0.27M-1.20M0.29M0.55M1.15M8.08M-8.20M-0.81M-0.31M1.06M7.69M0.97M-5.40M5.22M-4.78M
Ending Cash Balance 1.06M0.60M0.33M0.04M0.09M0.08M0.67M
Free Cash FlowFCF -0.47M-0.27M-8.60M-4.04M-3.24M-5.48M-13.59M-5.26M-3.84M-5.49M-4.95M-5.43M-7.14M-4.94M-4.27M-5.08M
Net Cash FlowNCF -0.47M-0.27M-1.17M0.28M0.55M1.16M8.06M-8.18M-0.82M-0.29M1.09M7.68M0.97M-5.41M5.22M-4.79M
Interest Paid 0.01M0.01M0.01M0.01M0.37M0.02M0.09M0.01M0.02M0.64M0.20M0.01M0.42M
Income Taxes PaidTaxes Paid 0.00M0.01M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.01M0.01M

Calidi Biotherapeutics Cash Flow Statement API

Pull Calidi Biotherapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CLDI&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY